Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Cash (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Change in Cash for 5 consecutive years, with -$18.2 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 263.44% to -$18.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.5 million through Dec 2025, up 52.86% year-over-year, with the annual reading at -$9.5 million for FY2025, 52.86% up from the prior year.
  • Change in Cash hit -$18.2 million in Q4 2025 for ARS Pharmaceuticals, down from $8.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $173.2 million in Q4 2022 to a low of -$122.7 million in Q1 2023.
  • Historically, Change in Cash has averaged $839800.0 across 5 years, with a median of -$7.7 million in 2022.
  • Biggest YoY gain for Change in Cash was 508.91% in 2023; the steepest drop was 1461.7% in 2023.
  • Year by year, Change in Cash stood at $121.5 million in 2021, then soared by 42.61% to $173.2 million in 2022, then tumbled by 93.97% to $10.4 million in 2023, then rose by 6.91% to $11.2 million in 2024, then crashed by 263.44% to -$18.2 million in 2025.
  • Business Quant data shows Change in Cash for SPRY at -$18.2 million in Q4 2025, $8.0 million in Q3 2025, and $11.7 million in Q2 2025.